Aslan Pharmaceuticals had bold ambitions to challenge Sanofi and Regeneron’s immunology blockbuster Dupixent, but now the cash-strapped biotech has run out of road.

Roche’s Genentech has scuttled its SHP2 inhibitor pact, returning the rights to Relay Therapeutics after plowing more than $120 million into the alliance. The action is the latest in a series of terminations of SHP2 deals.

Cardurion Pharmaceuticals was made flush in 2021 thanks to a $300 million investment from Bain Capital. Now, the biotech is looking to challenge the statin-dominated cardiovascular status quo with a $260 million series B fundraising round.

The digital health developer Huma announced that it has raised $80 million to help carry it through the ongoing rollout of its cloud-based platform for managing patients regardless of their specific disease.

Masimo has asked a federal court to intervene in its ongoing proxy fight with Politan Capital Management, with a lawsuit that seeks to force the activist investor to “correct material misstatements and omissions” in its materials sent to shareholders, the company said.

Sionna Therapeutics has quickly found a use for some of its $182 million series C haul, inking a deal with AbbVie to add three clinical-phase candidates to its burgeoning pipeline of cystic fibrosis prospects.

With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in this red-hot area of neuroscience R&D.

Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur Technologies.

After previously backing the startup, Edwards Lifesciences is exercising its option to acquire Innovalve and its mitral valve replacement implant.

Lexeo Therapeutics has guided its Friedreich ataxia (FA) gene therapy through an early test, generating evidence of improvements in cardiac status in early-phase trials. But the biotech ran into problems when testing the effect of the candidate on fitness and was left with a gap in evidence.